Corporate headquarters and press spokespersons:

Solvay Pharmaceuticals B.V.

• Address:
  C.J. VAN HOUTENLAAN, 36
  1381 CP WEESP
  Netherlands
   
• Mailing Address:
  P.O. BOX 900
  1380 DA WEESP
  Netherlands
   
• Spokesperson: mrs. P. Bossert
   
• Phone: +31 294 477000
  Fax: +31 294 480253
  E-mail: puck.bossert@solvay.com

Solvay Pharmaceuticals, Inc.

• Address:
  901 SAWYER ROAD
  MARIETTA GA 30062
  United States
   
• Mailing Address:
  901 SAWYER ROAD
  MARIETTA GA 30062
  United States
   
• Spokesperson: Mr. N Hirsch
   
• Phone: +1 770 5789000
  Fax: +1 770 5785597
  E-mail:neil.hirsch@solvay.com
  

Solvay completes acquisition of Fournier Pharma Solvay Pharmaceuticals launches DUODOPA® in 12 new European countries Solvay and Pronova Biocare sign license agreement for Omacor® Solvay and Berna Biotech sign a license agreement for Aerugen® Solvay finalizes agreement to buy Fournier Pharma MHRA requests further information on Cilansetron Cetrorelix progresses to full development in Solvay Pharmaceuticals for the treatment of Endometriosis in women Solvay Pharmaceuticals will supply Norway with special vaccines in the event of an influenza pandemic Parkinson's: Solvay Pharmaceuticals moves SLV 308 compound into phase III clinical development Solvay Pharmaceuticals completes acquisition of Neopharma in Sweden Solvay’s Fluvoxamine maleate is first drug approved for the treatment of social anxiety disorder in Japan Solvay welcomes outcome of Fenofibrate intervention and event lowering in diabetes (field) study Solvay and Berna Biotech sign a license agreement for Aerugen® Solvay Pharmaceuticals completes market authorization in 28 European countries for Duodopa® Bifeprunox: update on registration submission plan following clinical phase III results CILANSETRON; suspended registration activites in the U.S., while discussions in Europe continue Press release Solvay Pharmaceuticals signs additional agreement to get maximum global expansion for Androgel® Solvay Pharmaceuticals awarded $298 million, five-year contract by U.S. department of Health & Human Services for flu pandemic preparedness Solvay’s SLV 319 obesity candidate treatment advances in phase II clinical trials SOLVAY Extends its gastro-enterology portfolio with RACECADOTRIL , a treatment for acute diarrhoea. Solvay Pharmaceuticals, Inc. Announces the Sale of Baudette, Minn. Facilities to ANI Pharmaceuticals Phase 2 and 3 Clinical Data for Bifeprunox in Patients With Schizophrenia Showed Improvement of Symptoms and Maintenance of Stability With Fewer Metabolic Side Effects Versus Placebo Solvay Pharmaceuticals launches DUODOPA® in 12 new European countries 2005 Results First Quarter 2006 Results First half 2006 results Nine months 2006 results Solvay Pharmaceuticals Settles Lawsuit against Pseudo-Generic to CREON® MINIMICROSPHERES® Building out the fenofibrate franchise with a new fixed-dose combination product Solvay Pharmaceuticals and Wyeth announce submission of new drug application for Bifeprunox to treat schizophrenia Solvay, Quintiles announce five-year renewal of drug development strategic alliance U.S. Food and Drug Administration files new drug application for BIFEPRUNOX, submitted in October 2006 Solvay Pharmaceuticals withdraws its marketing authorization application for SYNORDIA® in Europe Solvay and Wyeth collaborate for discovery of anti-psychotics with novel mechanisms Solvay Pharmaceuticals files TEDISAMIL, a new cardiometabolic product for the treatment of atrial fibrillation and atrial flutter Solvay Pharmaceuticals to transfer fine Chemicals and vitamin D business to Dishman Pharmaceuticals and Chemicals Ltd First half 2007 results Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals announce receipt of an FDA action letter for bifeprunox, an investigational treatment for schizophrenia Nine months 2007 results New clinical data show Solvay’s fenofibrate cuts risk of main causes of vision loss in patients with type 2 diabetes Solvay Pharmaceuticals, Inc. Announces Retirement of CEO Laurence Downey and Appointment of Stephen Hill as New President and Chief Executive Officer 2007 Results FDA approval of Abbott's SIMCOR® marks start of co-promotion with Solvay Phase III studies of investigational Trilipix™ (SLV348/ABT-335), in combination with statins, meets primary endpoints on improving LDL, triglycerides and HDL SOLVAY PHARMACEUTICALS S.A. LAUNCHES FRIENDLY BID TO ACQUIRE INNOGENETICS First quarter 2008 results Phase III study of investigational TRILIPIX™ (SLV348/ABT-335), in combination with Astrazeneca’s CRESTOR® meets primary endpoints on key lipids Solvay Pharmaceuticals S.A. increases to eur 6.50 per share its initial tender offer to acquire Innogenetics n-3 PUFAs reduce mortality and hospital admissions in patients with symptomatic heart failure Solvay Pharmaceuticals acquires Innogenetics Nine months 2008 results Solvay welcomes FDA approval for Trilipix™ (fenofibric acid) Solvay’s cell-based production facility for Influenza vaccines validated and operational Solvay Pharmaceuticals announces the Influenza Research grant topic for 2010 Solvay opts for strategic refocus of activities